Whippany, NJ, United States of America

Xiaoling Lu

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 9.7

ph-index = 3

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations of Xiaoling Lu

Introduction

Xiaoling Lu is a notable inventor based in Whippany, NJ (US), recognized for his contributions to the field of pharmaceuticals. He holds a total of 8 patents, showcasing his innovative approach to developing new compounds and methods for medical applications.

Latest Patents

Among his latest patents is a significant invention related to antiproliferative compounds and methods of use thereof. This patent details a compound identified as 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or its enantiomers, mixtures of enantiomers, tautomers, or pharmaceutically acceptable salts. The methods described in this patent focus on treating, preventing, or managing multiple myeloma using these compounds. Additionally, the patent includes pharmaceutical compositions comprising these compounds and outlines methods for their use.

Career Highlights

Xiaoling Lu has had a distinguished career, working with prominent companies in the pharmaceutical industry. He has been associated with Celgene Corporation and Signal Pharmaceuticals, Inc., where he contributed to various innovative projects and research initiatives.

Collaborations

Throughout his career, Xiaoling has collaborated with several talented individuals, including Hon-Wah Man and Nanfei Zou, who have played significant roles in his research endeavors.

Conclusion

Xiaoling Lu's work in developing antiproliferative compounds and his contributions to the pharmaceutical industry highlight his innovative spirit and dedication to advancing medical science. His patents reflect a commitment to improving treatment options for serious health conditions, particularly multiple myeloma.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…